Reply to Torgrim Tandstad. The New Standard Adjuvant Treatment for High-risk Stage 1 Nonseminoma: Reducing the Treatment Burden and Maximizing Long-term Survival. Eur Urol 2020;77:352-3

Eur Urol. 2020 Dec;78(6):e220. doi: 10.1016/j.eururo.2020.05.023. Epub 2020 Jun 7.

Authors

Robert Huddart¹, Johnathan Joffe², Michael Cullen³

Affiliations

¹ The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: [email protected].
² The Leeds Teaching Hospitals NHS Trust, Leeds, UK.
³ University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

PMID: 32522389
DOI: 10.1016/j.eururo.2020.05.023

No abstract available

Publication types

Letter
Comment

MeSH terms

Chemotherapy, Adjuvant
Humans
Male
Reference Standards
Testicular Neoplasms* / drug therapy